Detect Cancer Early with SPOT-MAS

A single blood draw can screen for 5 common types of cancer. SPOT-MAS uses next-generation sequencing to detect ctDNA from tumor cells. Stay ahead of cancer with early detection.

Learn More About SPOT-MAS

A multi-cancer early detection test uses next generation sequencing to detect ctDNA from the tumor cells

Screening for 5 most common types of cancers (Breast, Liver, Lung, Stomach, Colon) with 1 simple blood draw.

Important Safety Information SPOT-MAS

The SPOT-MAS test is recommended for use in adults with elevated risk of cancer, such as those aged 40 years or older, those who carry genetic mutations, or those with unhealthy habits like smoking, drinking alcohol, getting hepatitis B, C. SPOT-MAS is not recommended for pregnant women or patients undergoing cancer treatment, or those with the history of bone marrow transplant, blood transfusion within 3 months.

The SPOT-MAS test is used to detect signals that suggest cancer through ctDNA released from cancer cells into the bloodstream and to predict the tumor origin of the cancer signal in the body. SPOT-MAS does not detect all cancers and not all cancers can be detected through ctDNA analysis. Therefore, SPOT-MAS should be used as recommended by the Doctor and as a supporting method for recommended routine cancer screening methods to help detect cancer EARLY.

It should be noted that SPOT-MAS is a screening test and SPOT-MAS results should be consulted by a healthcare expert, or a genetic specialist. The Doctor will interpret the results of the SPOT-MAS test based on information of your medical history, clinical symptoms, and other signals. A negative SPOT-MAS test result “no ctDNA signal detected” does not exclude all possibilities of having cancer, so it is still necessary for the routine check-up of cancer as recommended by a healthcare professional. With a positive SPOT-MAS test result “ctDNA signal detected” and the origin of cancer prediction, the Doctor will recommend follow-up diagnostic methods such as imaging, biopsy, etc. to confirm the presence of cancer. False positives and false negatives do occur.

When using SPOT-MAS tests for early cancer screening, some limitations of ctDNA analysis method released from cancer cells into peripheral blood should be kept in mind about the following results:

- A negative result (no ctDNA signal yet) does not completely exclude the presence of cancer because the tumor might be out of the screening range (5 types) or located in the location where it is difficult for ctDNA to release, or the secondary cancer has completely different methylation changes than the primary cancer.

- The sensitivity is 72.4%, meaning that for every 100 cases of cancer, about 28 cases will be missed. It is recommended that this test should be used as an adjunct to screening, not a substitute for current recommended routine cancer screening methods.

- A positive result (ctDNA signal detected) does not completely confirm that the participant has cancer due to some special physiological or pathological circumstances can produce a “false positive” result. The specificity is 97%, which means that for every 100 cancer-free cases, about 3 will have positive to ctDNA signals.

- The positive predictive value of the test is 58.1%, which means that for every 100 cases that are positive, 60 will have cancer. Therefore, a positive result should be consulted by an oncologist, genetic specialist and confirmed with medical imaging tests.

- The tumor origin is predicted based on machine learning algorithms that analyze 4 different features of ctDNA released to the bloodstream and predict the tumor origins with the accuracy of 84%. However, these features of ctDNA can be duplicated leading to the inability to completely identify the tumor origin.

Source: GENE SOLUTIONS